Usefulness of pindolol for treatment of neurocardiogenic syncope

This study evaluated the efficacy of pindolol, a noncardioselective β blocker with intrinsic sympathetic activity, on neurocardiogenic syncope using a head-up tilt-table test in 66 patients. Pindolol was equally effective in men and women and the 2 age groups (>60 and <60 years) of the study cohort. The earliest benefit was seen ≤3 days after initiating treatment. Side effects were better tolerated in younger patients (age <60 years).